About Novartis Corporation Malaysia Sdn Bhd
Novartis Corporation Malaysia Sdn Bhd: A Leading Pharmaceutical Multinational Company in Malaysia
Novartis Corporation Malaysia Sdn Bhd is a subsidiary of Novartis International AG, a Swiss multinational pharmaceutical company that operates in over 140 countries worldwide. Established in 1971, Novartis has had a long heritage and legacy in Malaysia. Over the years, it has grown to become one of the largest pharmaceutical multinational companies in the country that employs approximately 750 associates who work in the Pharmaceutical, Oncology, Sandoz (generics) and Business Services divisions.
The company's mission is to discover new ways to improve and extend people's lives by developing innovative medicines and treatments for some of the world's most challenging diseases. Novartis is committed to providing high-quality healthcare solutions that meet patients' needs while also contributing to society's well-being.
Pharmaceutical Division
Novartis' Pharmaceutical division focuses on developing innovative medicines for various therapeutic areas such as cardiovascular disease, respiratory disease, neuroscience, immunology and dermatology. The company invests heavily in research and development (R&D) activities to discover new drugs that can help patients live longer and healthier lives.
One of Novartis' flagship products is Entresto®, a medication used for treating heart failure with reduced ejection fraction (HFrEF). Entresto® has been shown to reduce hospitalizations due to heart failure by up to 20% compared with traditional treatments. Another notable product from Novartis' portfolio is Cosentyx®, which is used for treating psoriasis and psoriatic arthritis.
Oncology Division
Novartis' Oncology division focuses on developing innovative cancer treatments that can help patients fight cancer more effectively. The company invests heavily in R&D activities aimed at discovering new therapies for various types of cancers such as breast cancer, lung cancer, leukemia and lymphoma.
One of Novartis' flagship products from its oncology portfolio is Kymriah®, a CAR-T cell therapy used for treating certain types of blood cancers such as acute lymphoblastic leukemia (ALL) or diffuse large B-cell lymphoma (DLBCL). Kymriah® works by reprogramming a patient's own immune cells so they can recognize and attack cancer cells more effectively.
Sandoz Division
Novartis' Sandoz division focuses on developing high-quality generic drugs that are affordable yet effective alternatives to branded medications. The division offers a wide range of generic drugs across various therapeutic areas such as cardiovascular disease, respiratory disease, oncology and neurology.
Business Services Division
The Business Services division provides support services across all other divisions within Novartis Corporation Malaysia Sdn Bhd. These services include finance & accounting operations management; human resources management; information technology management; procurement & logistics management; quality assurance & control management; regulatory affairs & compliance management; sales & marketing operations management; strategic planning & business development management among others.
In conclusion,
Novaris Corporation Malaysia Sdn Bhd has established itself as one of the leading pharmaceutical multinational companies operating within Malaysian borders today through its commitment towards innovation-driven research aimed at improving people’s health outcomes while also contributing positively towards society’s well-being.
With an extensive product portfolio spanning across multiple therapeutic areas including but not limited too Cardiovascular Disease , Respiratory Disease , Neuroscience , Immunology , Dermatology among others ; coupled with an experienced team comprising over 750 associates working across four different divisions namely Pharmaceuticals , Oncology , Sandos(Generics)and Business Services ; it comes as no surprise why this organization continues being ranked amongst top players within this industry.
Through continued investment into R&D activities aimed at discovering novel therapies capable enough at combating some world’s most challenging diseases alongside their unwavering commitment towards providing high-quality healthcare solutions tailored specifically towards meeting patient needs ; we can only expect nothing but continued growth from this organization moving forward!
novartis.com.my
